Antisense oligonucleotides directed against XIAP sensitise cancer cells to chemotherapeutic drugs in vitro (McManus et al, 2004) and those developed by Aegera Therapeutics Inc. are currently being evaluated in phase I and II clinical trials (Cummings et al, 2005; Schimmer et al, 2006). The gene discussed is XIAP; the disease is cancer.